These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 31306366

  • 1. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Wu J, Ye Y, Li C, Zhou W, Chang R.
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
    [Abstract] [Full Text] [Related]

  • 2. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
    Li C, Cheng W, Guo J, Guan W.
    Int J Chron Obstruct Pulmon Dis; 2019 Sep; 14():799-808. PubMed ID: 31114181
    [Abstract] [Full Text] [Related]

  • 3. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
    Lee HW, Park J, Jang EJ, Lee CH.
    Respir Res; 2020 Nov 25; 21(1):310. PubMed ID: 33238986
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.
    Aziz MIA, Tan LE, Wu DB, Pearce F, Chua GSW, Lin L, Tan PT, Ng K.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 25; 13():3203-3231. PubMed ID: 30349228
    [Abstract] [Full Text] [Related]

  • 5. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
    Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 25; 12():3469-3485. PubMed ID: 29255354
    [Abstract] [Full Text] [Related]

  • 6. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
    Xia N, Wang H, Nie X.
    PLoS One; 2015 Nov 25; 10(9):e0137904. PubMed ID: 26378450
    [Abstract] [Full Text] [Related]

  • 7. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N.
    Int J Chron Obstruct Pulmon Dis; 2015 Nov 25; 10():1093-102. PubMed ID: 26089659
    [Abstract] [Full Text] [Related]

  • 8. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R, Gupta N, Sethi S.
    Expert Rev Clin Pharmacol; 2020 Feb 25; 13(2):103-113. PubMed ID: 31951778
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.
    Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.
    Int J Chron Obstruct Pulmon Dis; 2017 Feb 25; 12():367-381. PubMed ID: 28176892
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
    Ther Adv Respir Dis; 2015 Apr 25; 9(2):49-55. PubMed ID: 25691493
    [Abstract] [Full Text] [Related]

  • 11. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 12. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 22; 11():2885-2895. PubMed ID: 27932872
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 22; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 14. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH, Rabe KF, Welte T.
    Pulm Pharmacol Ther; 2017 Aug 22; 45():19-33. PubMed ID: 28389258
    [Abstract] [Full Text] [Related]

  • 15. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 22; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
    Kwak MS, Kim E, Jang EJ, Kim HJ, Lee CH.
    Int J Chron Obstruct Pulmon Dis; 2015 Aug 22; 10():2365-76. PubMed ID: 26604734
    [Abstract] [Full Text] [Related]

  • 17. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 22; 12():2917-2928. PubMed ID: 29062229
    [Abstract] [Full Text] [Related]

  • 18. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
    Tashkin DP, Fabbri LM.
    Respir Res; 2010 Oct 29; 11(1):149. PubMed ID: 21034447
    [Abstract] [Full Text] [Related]

  • 19. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct 29; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 20. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S, Criner GJ.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 29; 12():2307-2312. PubMed ID: 28814858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.